Driving results for early Commercial stage med-tech and life sciences companies through experience and strategic execution.

ABOUT

2409 Advisors provides fractional leadership and advisory services to help early-stage Med-Tech and Life Sciences companies secure capital, navigate regulatory requirements, improve operational efficiency, and execute commercial launch strategies that drive measurable growth.

TEAM

Chris Mathia is the founder of 2409 Advisors and an experienced healthcare executive with two successful exits. Most recently, he served as CEO of TheraB Medical Products, where he led commercial and operational launch planning, secured funding, played a key role in TheraB’s solution design and manufacture transfer, and guided the company through FDA submission, resulting in 510(k) clearance in January 2026 for its flagship product, SnugLit, a portable phototherapy device for the treatment of neonatal jaundice.

TheraB was acquired by Natus Sensory in February 2026.

Previously, Chris served as CEO of Innara Health, where he led a company reorganization, secured funding, drove commercial and operational initiatives, and oversaw the 510(k)-cleared launch of NTrainer® 2.0, culminating in the company’s acquisition by Cardinal Health in early 2023.

Earlier in his career, Chris held leadership roles with Cerner Corporation, Hyland Software, Thomson Reuters, B. Braun, and Medline Industries.

With a passion for pediatrics, Chris specializes in commercialization and go-to-market strategies for early-stage medical device and life science companies.

He is an alumnus of the MedTech Innovator 2020 Pediatric Cohort and a recipient of a $50,000 non-dilutive grant from Children’s National’s “Make Your Pitch for Kids” competition. Chris holds a B.S. degree in Political Science from the University of Kansas.

Current Projects

  • CEO focused on capital raise while developing organizational infrastructure and commercialization strategy for pre-FDA cleared company focused on Children’s health. - Exited to Natus Sensory

  • Fractional CRO/CMO supporting capital raise activities while developing commercial launch and reimbursement strategy for pre-FDA cleared company focused on Maternal & Children’s health.

  • Entrepreneur in Residence for nationally recognized innovation intermediary focused on providing comprehensive advisory services and support for early-stage, NIH, BARDA, and ARPA-H funded organizations.

  • Advisor for venture capital firm with interests in expanding portfolio to include Life Sciences and Healthcare Technology companies.

Stay in the know

Occasionally, we’ll release a newsletter or an update highlighting our client’s success. Feel free to sign up for a “no-solicit” update.